(Q37777055)

23 August 2017

1 reference

title

PPARγ and chronic kidney disease (English)

1 reference

23 August 2017

Agnes B. Fogo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20676693

14 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20676693

14 June 2024

publication date

30 July 2010

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s00467-010-1602-2.pdf

file format

Portable Document Format

1 reference

DOI

https://api.crossref.org/works/10.1007/S00467-010-1602-2

http://link.springer.com/article/10.1007/s00467-010-1602-2/fulltext.html

14 June 2024

1 reference

https://api.crossref.org/works/10.1007/S00467-010-1602-2

http://link.springer.com/content/pdf/10.1007/s00467-010-1602-2

14 June 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S00467-010-1602-2

14 June 2024

1 reference

23 August 2017

volume

26

1 reference

23 August 2017

issue

3

1 reference

23 August 2017

page(s)

347-351

1 reference

https://scigraph.springernature.com/pub.10.1007/s00467-010-1602-2

23 August 2017

exact match

0 references

cites work

Protection of the kidney by thiazolidinediones: an assessment from bench to bedside

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Antiproteinuric and anti-inflammatory effects of thiazolidinedione

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Peroxisome proliferator-activated receptor gamma agonists in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Effects of troglitazone and temocapril in spontaneously hypertensive rats with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Pioglitazone attenuates TGF-beta(1)-induction of fibronectin synthesis and its splicing variant in human mesangial cells via activation of peroxisome proliferator-activated receptor (PPAR)gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Pioglitazone inhibits cell growth and reduces matrix production in human kidney fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Angiotensin inhibition decreases progression of advanced atherosclerosis and stabilizes established atherosclerotic plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Pioglitazone increases renal tubular cell albumin uptake but limits proinflammatory and fibrotic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

PPARgamma-agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Reduction of proteinuria by rosiglitazone in non-diabetic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00467-010-1602-2

Microangiopathic injury and augmented PAI-1 in human diabetic nephropathy

21 January 2018

1 reference

12 December 2020

Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma

1 reference

12 December 2020

Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats

1 reference

12 December 2020

Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells

1 reference

12 December 2020

Chronic allograft nephropathy: expression and localization of PAI-1 and PPAR-gamma

1 reference

12 December 2020

PPAR-gamma agonist protects podocytes from injury

1 reference

12 December 2020

Peroxisome proliferator-activated receptor gamma control of dendritic cell function contributes to development of CD4+ T cell anergy

1 reference

12 December 2020

PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease

1 reference

12 December 2020

Identifiers

DOI

1 reference

23 August 2017

1 reference